| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | 0 | 0 | 0 | 19.573 | 57.359 |
| Total Income - EUR | - | - | - | - | - | 657 | 6.889 | 9.163 | 36.996 | 73.865 |
| Total Expenses - EUR | - | - | - | - | - | 17.937 | 25.810 | 28.590 | 28.519 | 24.439 |
| Gross Profit/Loss - EUR | - | - | - | - | - | -17.280 | -18.921 | -19.427 | 8.477 | 49.427 |
| Net Profit/Loss - EUR | - | - | - | - | - | -17.280 | -18.921 | -19.427 | 8.282 | 47.706 |
| Employees | - | - | - | - | - | 3 | 4 | 4 | 3 | 1 |
Check the financial reports for the company - X&Nmed S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | 32.086 | 27.698 | 24.096 | 28.460 | 64.139 |
| Current Assets | - | - | - | - | - | 42.064 | 1.187 | 928 | 8.775 | 11.529 |
| Inventories | - | - | - | - | - | 183 | 179 | 179 | 0 | 0 |
| Receivables | - | - | - | - | - | 41.347 | 235 | 260 | 754 | 1.912 |
| Cash | - | - | - | - | - | 535 | 774 | 489 | 8.021 | 9.617 |
| Shareholders Funds | - | - | - | - | - | -18.957 | -37.781 | -57.326 | -48.870 | 5.178 |
| Social Capital | - | - | - | - | - | 41 | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | 51.761 | 32.687 | 51.952 | 60.639 | 54.892 |
| Income in Advance | - | - | - | - | - | 41.347 | 33.979 | 30.397 | 25.466 | 15.598 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8690 - 8690" | |||||||||
| CAEN Financial Year |
8690
|
|||||||||
Comments - X&Nmed S.r.l.